Imaging dopaminergic dysfunction as a surrogate marker of neuropathology in a small-animal model of HIV

Molecular Imaging

Volumn 13, Issue 9, 2014, Pages

  Lee, Dianne E ^a,b,c   Reid, William C ^a,b,c   Ibrahim, Wael G ^a,b,c   Peterson, Kristin L ^a,b,c   Lentz, Margaret R ^a,b,c   Maric, Dragan ^a,b,c   Choyke, Peter L ^a,b,c   Jagoda, Elaine M ^a,b,c   Hammoud, Dima A ^a,b,c,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; AMINO ACIDS; BRAIN; DISEASES; MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RATS; VIRUSES;

AGE-MATCHED CONTROLS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOHISTOCHEMISTRY; POSITRON EMISSION TOMOGRAPHY (PET); REFERENCE MODELING; SMALL ANIMAL MODEL; TIME-ACTIVITY CURVES; TYROSINE HYDROXYLASE;

MOLECULAR IMAGING;

BENZAMIDE DERIVATIVE; BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL; BRAIN; DISEASE MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PATHOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RAT; SCINTISCANNING; TRANSGENIC RAT;

ANIMALS; BENZAMIDES; BIOMARKERS; BRAIN; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RADIOPHARMACEUTICALS; RATS; RATS, TRANSGENIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 84911374879     PISSN: 15353508     EISSN: 15360121     Source Type: Journal    
DOI: 10.2310/7290.2014.00031     Document Type: Article

References (50)

1. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurol 2010;75:2087-2096, doi:10. 1212/WNL.0b013e318200d727.
2. Bieniasz PD, Cullen BR. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J Virol 2000;74: 9868-9877, doi:10.1128/JVI.74.21.9868-9877.2000.
3. Reid W, Sadowska M, Denaro F, et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 2001;98:9271-9276, doi:10.1073/ pnas.161290298.
4. Moran LM, Aksenov MY, Booze RM, et al. Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr HIV Res 2012;10:415-424, doi:10.2174/157016212802138788.
5. Moran LM, Booze RM, Mactutus CF. Time and time again: temporal processing demands implicate perceptual and gating deficits in the HIV-1 transgenic rat. J Neuroimmune Pharmacol 2013;8:988-997, doi:10.1007/s11481-013-9472-6.
6. Lashomb AL, Vigorito M, Chang SL. Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J Neurovirol 2009;15:14-24, doi:10.1080/ 13550280802232996.
7. Peng J, Vigorito M, Liu X, et al. The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J Neuroimmunol 2010; 218:94-101, doi:10.1016/j.jneuroim.2009.09.014.
8. Moran LM, Booze RM, Webb KM, et al. Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp Neurol 2013;239:139-147, doi:10.1016/j.expneurol.2012.10.008.
9. Webb KM, Aksenov MY, Mactutus CF, et al. Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat. J Neurovirol 2010;16:168-173, doi:10.3109/13550281003690177.
10. Nath A, Anderson C, Jones M, et al. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J Psychopharmacol 2000;14:222-227, doi:10.1177/026988110001400305.
11. Hersh BP, Rajendran PR, Battinelli D. Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART. Neurology 2001;56:278-279, doi:10.1212/WNL.56.2.278.
12. Koutsilieri E, ter Meulen V, Riederer P. Neurotransmission in HIV associated dementia: a short review. J Neural Transm 2001;108: 767-775, doi:10.1007/s007020170051.
13. Lopez OL, Smith G, Meltzer CC, et al. Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:184-192.
14. Mirsattari SM, Power C, Nath A. Parkinsonism with HIV infection. Mov Disord 1998;13:684-689, doi:10.1002/mds.870130413.
15. Mukherjee J, Christian BT, Narayanan TK, et al. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 2005 1032. 77-84.
16. Paxinos G, Watson C. The rat brain. In; Stereotaxic coordinates. Compact 6th ed. London, UK: Academic Press, Elsevier; 2009.
17. Schweinhardt P, Fransson P, Olson L, et al. A template for spatial normalisation of MR images of the rat brain. J Neurosci Methods 2003;129:105-113, doi:10.1016/S0165-0270(03)00192-4.
18. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007;315:1267-1270, doi:10.1126/science.1137073.
19. Farde L, Hall H, Ehrin E, et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-261, doi:10.1126/science.2867601.
20. Watabe H, Channing MA, Der MG, et al. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Bood Flow Metab 2000; 20:899-909, doi:10.1097/00004647-200006000-00002.
21. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-158, doi:10.1006/ nimg.1996.0066.
22. Lammertsma AA, Bench CJ, Hume SP, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52, doi:10.1097/00004647-199601000-00005.
23. Slifstein M, Kegeles LS, Xu X, et al. Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 2010;64:350-362, doi:10.1002/syn.20734.
24. Chang L, Wang GJ, Volkow ND, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage 2008;42:869-878, doi:10.1016/ j.neuroimage.2008.05.011.
25. Vigorito M, LaShomb AL, Chang SL. Spatial learning and memory in HIV-1 transgenic rats. J Neuroimmune Pharmacol 2007;2:319-328, doi:10.1007/s11481-007-9078-y.
26. Torres-Munoz J, Stockton P, Tacoronte N, et al. Detection of HIV-1 gene sequences in hippocampal neurons isolated from postmortem AIDS brains by laser capture microdissection. J Neuropathol Exp Neurol 2001;60:885-892.
27. Torres-Munoz JE, Nunez M, Petito CK. Successful application of hyperbranched multidisplacement genomic amplification to detect HIV-1 sequences in single neurons removed from autopsy brain sections by laser capture microdissection. J Mol Diagn 2008;10: 317-324, doi:10.2353/jmoldx.2008.070074.
28. Kovalevich J, Langford D. Neuronal toxicity in HIV CNS disease. Future Virol 2012;7:687-698, doi:10.2217/fvl.12.57.
29. Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of Human Immunodeficiency Virus-1: Viral Proteins and Axonal Transport. Neurotox Res 2011;21:79-89, doi:10.1007/s12640-011-9279-2.
30. Guha D, Nagilla P, Redinger C, et al. Neuronal apoptosis by HIV-1 Vpr: contribution of proinflammatory molecular networks from infected target cells. J Neuroinflammation 2012;9:138, doi:10.1186/ 1742-2094-9-138.
31. Rao JS, Kim HW, Kellom M, et al. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in brain of HIV-1 transgenic rats. J Neuroinflammation 2011;8:101, doi:10.1186/1742-2094-8-101.
32. Agrawal L, Louboutin JP, Reyes BA, et al. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiol Dis 2012;45:657-670, doi:10.1016/j.nbd.2011.10.005.
33. Hu S, Sheng WS, Lokensgard JR, et al. Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol 2009;15:401-410, doi:10.3109/13550280903296346.
34. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4:702-710, doi:10.1038/89490.
35. Radja F, Kay DG, Albrecht S, et al. Oligodendrocyte-specific expression of human immunodeficiency virus type 1 Nef in transgenic mice leads to vacuolar myelopathy and alters oligodendrocyte phenotype in vitro. J Virol 2003;77:11745-11753, doi:10. 1128/JVI.77.21.11745-11753.2003.
36. Nath A, Haughey NJ, Jones M, et al. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 2000;47:186-194, doi:10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.0.CO;2-3.
37. Keswani SC, Polley M, Pardo CA, et al. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 2003;54:287-296, doi:10.1002/ana.10645.
38. Hudson L, Liu J, Nath A, et al. Detection of the human immunodeficiency virus regulatory protein tat in CNS tissues. J Neurovirol 2000;6:145-155, doi:10.3109/13550280009013158.
39. Yeung MC, Pulliam L, Lau AS. The HIV envelope protein gp120 is toxic to human brain-cell cultures through the induction of interleukin-6 and tumor necrosis factor-alpha. AIDS 1995;9:137-143, doi:10.1097/00002030-199509020-00004.
40. Ferris MJ, Frederick-Duus D, Fadel J, et al. In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 2009;63:181-185, doi:10.1002/syn.20594.
41. Kessler RM, Ansari MS, Riccardi P, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991-2001, doi:10.1038/sj.npp.1301108.
42. Riccardi P, Li R, Ansari MS, et al. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006;31:1016-1026, doi:10.1038/sj.npp.1300916.
43. Narendran R, Frankle WG, Mason NS, et al. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride. Synapse 2009;63:447-461, doi:10.1002/syn.20628.
44. Tantawy MN, Jones CK, Baldwin RM, et al. [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. Nucl Med Biol 2009;36:931-940, doi:10.1016/j.nucmedbio.2009.06.007.
45. Honer M, Bruhlmeier M, Missimer J, et al. Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. J Nucl Med 2004;45:464-470.
46. Martic-Kehl MI, Ametamey SM, Alf MF, et al. Impact of inherent variability and experimental parameters on the reliability of small animal PET data. EJNMMI Res 2012;2:26, doi:10.1186/2191-219X-2-26.
47. Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002;46: 170-188, doi:10.1002/syn.10128.
48. Dunn JT, Clark-Papasavas C, Marsden P, et al. Establishing testretest reliability of an adapted [(18)F]fallypride imaging protocol in older people. J Cereb Bood Flow Metab 2013;33:1098-1103, doi:10.1038/jcbfm.2013.55.
49. Mukherjee J, Narayanan TK, Christian BT, et al. In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist (11)C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate. Synapse 2000;37:64-70, doi:10.1002/(SICI)1098- 2396(200007)37:1<64::AID-SYN7>3.0.CO;2-F.
50. Tantawy MN, Peterson TE, Jones CK, et al. Impact of isoflurane anesthesia on D2 receptor occupancy by [18F]fallypride measured by microPET with a modified Logan plot. Synapse 2011;65:1173-1180, doi:10.1002/syn.20955.